CRISPR Therapeutics AG

Some of the best links we picked up around the internet

SyNTase Gene Editor Corrects Antitrypsin...

Oct. 15, 2025

CRISPR Therapeutics has presented preclinical data showing that its investigational therapy CTX460 can correct the SERPINA1 Z (E342K) mutation...

CMN Weekly (8 August 2025) - Your Weekly CRISPR...

CMN Weekly

Aug. 8, 2025

Some of the best links we picked up around the internet

CMN Weekly (11 July 2025) - Your Weekly CRISPR...

CMN Weekly

Jul. 11, 2025

Some of the best links we picked up around the internet

CMN Weekly (4 July 2025) - Your Weekly CRISPR...

CMN Weekly

Jul. 4, 2025

Some of the best links we picked up around the internet

CMN Weekly (27 June 2025) - Your Weekly CRISPR...

CMN Weekly

Jun. 27, 2025

Some of the best links we picked up around the internet

CMN Weekly (30 May 2025) - Your Weekly CRISPR...

CMN Weekly

May. 30, 2025

Some of the best links we picked up around the internet

CMN Weekly (23 May 2025) - Your Weekly CRISPR...

CMN Weekly

May. 23, 2025

Some of the best links we picked up around the internet

CRISPR Therapeutics AG

Refractory Autoimmune Disease, (NCT06925542)
Sponsors:
CRISPR Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Relapsed/Refractory Hematologic Malignancies (NCT06492304)
Sponsors:
CRISPR Therapeutics

IND Enabling

Phase I

Phase II

Phase III

Hematologic and Solid Malignancies, (NCT06208878)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Cardiovascular Disease or Calcific Aortic Valve Stenosis, (ACTRN12623001095651p)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Refractory Dyslipidemias, (ACTRN12623000809639)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05477563)
Sponsors:
Vertex Pharmaceuticals Incorporated

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory Solid Tumors, (NCT05795595)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III

Relapsed or Refractory B-Cell Malignancies, (NCT05643742)
Sponsors:
CRISPR Therapeutics AG

IND Enabling

Phase I

Phase II

Phase III